Last reviewed · How we verify
Renal Cell Carcinoma
Approved treatments
- Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Cometriq · Exelixis
Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis. - Torisel · Pfizer
Torisel works by blocking the mTOR protein, which is involved in cell growth and division. - Nexavar · Bayer
- Yervoy · Bristol-Myers Squibb
Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells. - Bavencio · Merck KGaA
Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells. - Bavencio · Pfizer
- Lenvima · Eisai
Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells. - Afinitor · Novartis
Afinitor works by blocking the mTOR protein, which is involved in cell growth and division. - Sutent · Pfizer
Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT. - Sunitinib Malate · Pfizer
Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET. - Nexavar · Fujian Medical University
- Cometriq · Exelixis Inc
Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis. - Afinitor · Central European Society for Anticancer Drug Research
- Syprine · Bausch Health
- Yervoy · Bristol-Myers Squibb
- Inlyta · Pfizer
Axitinib inhibits VEGFR-1, VEGFR-2, and VEGFR-3 to block pathologic angiogenesis and tumor growth. - Sutent · Pfizer
Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression. - Votrient · Tracon Pharmaceuticals Inc.
- Rapamune · Pfizer
Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells. - Inlyta · Pfizer
Inlyta works by blocking the activity of the mast/stem cell growth factor receptor Kit, which is involved in the growth and spread of cancer cells. - Rapamycin · Institut National de la Santé Et de la Recherche Médicale, France
Clinical guidelines
- FDA label — 1L
INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). - FDA label — 1L
INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). - FDA label — 2L
INLYTA as a single agent is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. - FDA label — 1L
Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma. - FDA label — 1L
INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). - FDA label — 1L
INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). - FDA label — 2L
INLYTA as a single agent is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Renal Cell Carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Renal Cell Carcinoma treatment landscape brief
- Renal Cell Carcinoma treatment updates RSS